Animal Drug Compounding Market Study by Product Type, Animal, and Administration

The global animal drug compounding market size was estimated at USD 1.52 billion in 2024 and is projected to reach USD 2.45 billion by 2030, growing at a CAGR of 8.29% from 2025 to 2030. The industry is primarily driven by the rising demand for customized pharmaceutical solutions to meet the specific therapeutic requirements of diverse animal species.

The limited availability of FDA-approved veterinary drugs across all species and medical conditions necessitates the use of compounded medications. These specialized formulations allow veterinarians to provide tailored treatments when no commercial alternative exists, ensuring optimal health outcomes. For example, because there is currently no FDA-approved medication for treating megacolon in felines, and the effective treatment Cisapride was removed from the U.S. market in 2000, compounded versions of the drug remain the only viable pro-kinetic therapy for cats with chronic constipation.

Key Market Trends & Insights

• North America dominated the global market, accounting for a revenue share of 40.51% in 2024.
• The U.S. led the North American region, maintaining the largest individual revenue share in 2024.
• By product, CNS agents led the market with a significant revenue share of 33.38% in 2024.
• By animal type, the companion animal segment was the primary contributor, holding 73.65% of the market share in 2024.
• By route of administration, the oral segment remained the most popular, capturing 53.34% of the revenue in 2024.

Download a free sample PDF of the Animal Drug Compounding Market Intelligence Study by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 1.52 Billion
• 2030 Projected Market Size: USD 2.45 Billion
• CAGR (2025-2030): 8.29%
• North America: Largest market in 2024
• Asia Pacific: Fastest-Growing Market

Competitive Landscape

The market is highly competitive and fragmented, characterized by a mix of large-scale providers and specialized local pharmacies. Key players frequently employ strategies such as geographic expansion, product innovation, and strategic mergers to strengthen their presence. The industry is currently experiencing a moderate to high level of innovation, driven by continuous research into stable and palatable drug delivery systems.

Prominent Companies

• WEDGEWOOD PHARMACY
• Vimian
• Pharmaca
• Akina Animal Health
• Triangle Compounding
• Davis Islands Pharmacy and Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Pharmacy of Cary
• Miller’s Pharmacy

Recent Developments

• In November 2024, My Compounding, a leading Brisbane-based pharmacy, announced a nationwide expansion to offer personalized medication solutions. This move establishes the firm as a major participant in the delivery of customized veterinary care across broader territories.
• In May 2024, Mixlab successfully acquired NexGen Animal Health, extending its tech-enabled compounding services from companion animals to the large animal and equine sectors. The acquisition aims to leverage Mixlab’s proprietary platform to improve production efficiency for large animal practitioners.
• In December 2024, Grey Wolf Animal Health Corp completed the purchase of The Compounding Pharmacy of Manitoba for USD 22.5 million, a strategic move to broaden its customer base and improve access to specialized compounded medications in the Canadian market.

Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.

Conclusion

The animal drug compounding market is set for sustained growth as pet owners increasingly seek human-grade precision in veterinary care and regulatory bodies provide clearer frameworks for safe compounding practices.